Outlook Therapeutics reports Q3 2026 results, says FDA approved Lytenava
Outlook Therapeutics said it released third-quarter fiscal 2026 results and hosted a call, while management highlighted FDA approval of Lytenava for wet AMD in the U.S.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.